Avita Medical sees FY25 revenue $100M-$106M

Expects to generate free cash flow in the second half of 2025. “In the fourth quarter, we reported a $4.1 million decline in operating expenses compared to the third quarter, reflecting our continued operational efficiencies,” said David O’Toole, CFO of Avita Medical (RCEL). “Moreover, our strategic focus on streamlining expenses contributed to a decrease in the use of cash for the fourth quarter compared to the third quarter. This downward trend is expected to continue over the next three quarters as we work toward generating free cash flow in the second half of the year and achieving GAAP profitability in the fourth quarter of 2025.”